金斯瑞生物科技(1548.HK)24年报点评:细胞治疗业务解除并表 各持续经营业务版块25年趋势向好 利润端有望持续为正

海通国际
14 Mar

公告。公司发布2024 年度业绩,持续经营业务收入约594.5 百万美元,同比增长6.1%,持续经营业务毛利约为272.1 百万美元,同比保持稳定;净利润约为29 亿美元,同期亏损约为355.1百万美元,其中,2024 年持续经营业务的亏损约为173.8 百万美元, 持续经营业务经调整净利润约为59.8 百万美元,同比增长2.9%。生命科学板块坚持全球化本土策略,产能扩张同步提升运营效率。生命科学...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10